Added to YB: 2026-09-10
Pitch date: 2026-09-08
QURE [neutral]
uniQure N.V.
+0.63%
current return
Author Info
EAA Partners shares insights and investment theses on global companies, driven by in-depth research and long-term conviction. Sign up for the newsletter.
Company Info
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States.
Market Cap
$3.1B
Pitch Price
$45.71
Price Target
N/A
Dividend
N/A
EV/EBITDA
-15.82
P/E
-11.02
EV/Sales
151.49
Sector
Biotechnology
Category
special_situation
uniQure N.V. - $QURE
QURE (update): uniQure’s value rests almost entirely on AMT-130, the most advanced disease-modifying Huntington’s therapy in a field with no credible near-term competitor. After reversing its rejection of the externally controlled 3-year dataset, the FDA agreed the data may support accelerated approval, and uniQure filed a BLA requesting priority review; 75% slower progression was based on only 12 high-dose patients. The four-year readout and FDA filing decision are next, while the unfinished confirmatory-study protocol remains the key unresolved variable.
Read full article (35 min)